CCPM is Shocked and Gravely Disappointed with Additional Delay to Affordable Life-Saving Biologics

      

"Congress missed a critical opportunity to bend the long-term cost curve of health care through a workable pathway for biogenerics," said Annette Guarisco, CCPM Chairman. "Despite numerous economic studies, widespread media attention, patient outcry, and the support of the Administration for a more balanced approach, the Senate Health Care Reform bill went in the opposite direction by adding additional exclusivity to the already unacceptable 12 years of market exclusivity for brand products. They continue to overlook the irrefutable opportunity to truly constrain costs to benefit patients and purchasers."

CCPM supports public policies that facilitate timely access to affordable pharmaceuticals. Visit www.BiogenericsGetTheFacts.org for more information and to see what efforts are underway to tell Congress to prioritize patients and consumers - not drug company profits.

Coalition for a Competitive Pharmaceutical Market (CCPM)
Press Contact:
Merritt Group
Laura Feinberg, 703-390-1512
feinberg@merrittgrp.com